Changing over-the-counter ephedrine and pseudoephedrine products to prescription only: impacts on methamphetamine clandestine laboratory seizures.
Abstract
BACKGROUND
Clandestine laboratory operators commonly extract ephedrine and pseudoephedrine-precursor chemicals used to synthesize methamphetamine-from
over-the-counter cold/allergy/sinus products. To prevent this activity, two states, Oregon in 07/2006 and Mississippi in 07/2010,
implemented regulations classifying ephedrine and pseudoephedrine as Schedule III substances, making products containing them
available by prescription only. Using simple pre-regulation versus post-regulation comparisons, reports claim that the regulations
have substantially reduced clandestine laboratory seizures (an indicator of laboratory prevalence) in both states, motivating
efforts to implement similar regulation nationally. This study uses ARIMA-intervention time-series analysis to more rigorously
evaluate the regulations' impacts on laboratory seizures.
METHODS
Monthly counts of methamphetamine clandestine laboratory seizures were extracted from the Clandestine Laboratory Seizure System
(2000-early 2011) for Oregon, Mississippi and selected nearby states (for quasi-control).
FINDINGS
Seizures in Oregon and nearby western states largely bottomed out months before Oregon's regulation, and changed little thereafter.
No significant impact for Oregon's regulation was found. Mississippi and nearby states generally had elevated seizures before
Mississippi's regulation. Mississippi experienced a regulation-associated drop of 28.9 seizures (50.2%) in the series level
(p<0.01), while nearby states exhibited no comparable decline.
CONCLUSIONS
Oregon's regulation encountered a floor effect, making any sizable impact infeasible. Mississippi, however, realized a substantial
impact, suggesting that laboratories, if sufficiently extant, can be meaningfully impacted by prescription precursor regulation.
It follows that national prescription precursor regulation would have little impact in western states with low indicated laboratory
prevalence, but may be of significant use in regions facing higher indicated prevalence.
Links
Authors
Cunningham JK, Callaghan RC, Tong D, Liu LM, Li HY, Lattyak WJ
Institution
Department of Family and Community Medicine, The University of Arizona, Tucson, AZ, USA. jkcunnin@email.arizona.edu
Source
Drug and alcohol dependence 126:1-2 2012 Nov 1 pg 55-64MeSH
Central Nervous System StimulantsEphedrine
Humans
Legislation, Drug
Methamphetamine
Mississippi
Nonprescription Drugs
Oregon
Prescription Drugs
Pseudoephedrine
Software
Street Drugs
United States
Pub Type(s)
Journal ArticleLanguage
eng
PubMed ID
22592141
Log In

